: China recently approved Exdensur (severe asthma) and Blenrep (multiple myeloma).

Investors are "piling into" GSK due to several key shifts in the company's fundamentals:

: Global drug-pricing reforms and regulatory uncertainty in major markets like the US and China continue to pose valuation risks.

🎯 : GSK is scheduled to report its Q1 2026 earnings on April 29, 2026 , with analysts expecting revenue of roughly $10.24 billion .